Bacteriophage Therapy Against Antibiotic-Resistant Bacteria: A Critical Appraisal

Mahendra Pal^1, , Ravindra Zende², Alemayehu Bekele³, Tesfaye Rebuma⁴, Nidhi Panicker² and I Made Dwi Mertha Adnyana⁵

¹Narayan Consultancy of Veterinary Public Health, and Microbiology, B-103, Sapphire Lifestyle, Bharuch, Gujarat, India

²Department of Veterinary Public Health, Mumbai Veterinary College, Parel, Mumbai, Maharashtra, India

³Wallaga University School of Veterinary Medicine Department of Clinical Studies, Wallaga, Nekemte, Oromia Region, Ethiopia

⁴Shaggar City Administration Sebeta Subcity Agricultural Office, Sebeta, Oromia, Ethiopia

⁵Department of Indonesian Traditional Medicine, Faculty of Health, Universitas Hindu Indonesia, Denpasar, 80236, Indonesia

Cite this paper:
Mahendra Pal, Ravindra Zende, Alemayehu Bekele, Tesfaye Rebuma, Nidhi Panicker and I Made Dwi Mertha Adnyana. Bacteriophage Therapy Against Antibiotic-Resistant Bacteria: A Critical Appraisal. American Journal of Public Health Research. 2025; 13(2):67-73. doi: 10.12691/ajphr-13-2-5

Abstract

Bacteriophages are bacteria-specific viruses that reduce or eliminate pathogenic or nuisance bacteria. It helps treat bacterial infections in animals, humans, birds, fish, plants, and food materials. All phages have a head structure that can vary in size and shape. When a virulent phage infects a host bacterium, it replicates much faster than the host cell does, causes lysis and death, simultaneously liberating many progeny phages for another cycle by infecting new neighboring bacterial cells. Phages can be administered orally, topically, in drops, intravenously, or via inhalation. After a single dose, phages are resorbed and reach the bloodstream within 2–4 h and the internal organs within a duration of 10 h, eventually being eliminated from the body within three days. Phage therapy can be used in many animals, including poultry, swine, cattle, and sheep, to treat various bacterial diseases caused by Salmonella, Escherichia coli, and Campylobacter. In modern technology, bacteriophages are genetically modified and engineered in such a way as to capacitate the expression of proteins and target the gene networks of bacteria on which antibiotics fail to act directly. The potential in vivo elimination of phages, phage-neutralizing antibodies, reticuloendothelial system clearance of phages from the patients, and phage-resistant mutants are the major limitations of phages. However, bacteriophages offer several advantages over antibiotics, including high host specificity. Therefore, phage therapy is a promising alternative for mitigating the burden of antibiotic-resistant bacteria.

Keywords:
Antibiotics Bacteria Bacteriophages Phage Therapy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Henry M, Debarbieux L. Tools from viruses: Bacteriophage successes and beyond. Virology. 2012; 434 (2): 151–161.
[2]	Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. Journal of Infection in Developing Countries. 2014 13; 8(2): 129-36.
[3]	Górski A, Międzybrodzki R, Weber-Dąbrowska B, Fortuna W, Letkiewicz S, Rogóż P. Phage therapy: Combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Frontiers in Microbiology. 2016; 7: 1515.
[4]	D'Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. Research in Microbiology. 2007; 158 (7): 553-4.
[5]	Farha MA, Tu MM, Brown ED. Important challenges to finding new leads for new antibiotics. Current Opinion in Microbiology. 2025; 83: 102562.
[6]	Shasha SM, Sharon N, Inbar M. [Bacteriophages as antibacterial agents]. Harefuah. 2004; 143(2): 121-5, 166. Hebrew. PMID: 15143702.
[7]	Vinodkumar CS, Kalsurmath S, Neelagund YF. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian Journal of Pathology and Microbiology. 2008; 51(3): 360-6.
[8]	Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy: new applications for old resources. Trends in Microbiology. 2015; 23 (4): 185-91.
[9]	Viertel TM, Ritter K, Horz HP. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. Journal of Antimicrobial and Chemotherapy. 2014 Sep; 69(9): 2326-36.
[10]	Ho K. Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotic’s era. Perspective in Biology and Medicine. 2001; 44(1): 1-16.
[11]	Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrobial Agents and Chemotherapy. 2001; 45(3): 649-59.
[12]	Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World Journal of Gastrointestinal and Pharmacological Therapy. 2017 Aug 6; 8(3): 162-173.
[13]	Sridhar PN. Bacteriophage. http:// microrao.com/ micronotes/ bacteriophage.pdf. Accessed in: March 30, 2017.
[14]	Chernomordik AB. Bakteriofagi i ikh lechebno-profilakticheskoe primenenie [Bacteriophages and their therapeutic-prophylactic use]. Med Sestra. 1989; 48(6): 44-7. Russian. PMID: 2796659.
[15]	Emencheta SC, Onugwu AL, Kalu CF, Ezinkwo PN, Eze OC, Vila MM, Onuigbo EB. Bacteriophages as nanocarriers for targeted drug delivery and enhanced therapeutic effects. Materials Advances. 2024; 5 (3): 986-1016.
[16]	Encyclopedia Britannica. Bacteriophage. Available at: http://www.britannica.com/EBchecked/topic/48324/bacteriophage. Accessed in: April 30, 2017.
[17]	Jassim SA, Limoges RG. Impact of external forces on cyanophage-host interactions in aquatic ecosystems. World Journal of Microbiology and Biotechnology. 2013; 29 (10): 1751-62.
[18]	Jassim SA, Abdulamir AS, Abu Bakar F. Novel phage-based bio-processing of pathogenic Escherichia coli and its biofilms. World Journal of Microbiology and Biotechnology. 2012; 28(1): 47-60.
[19]	Edgar R, Friedman N, Molshanski-Mor S, Qimron U. Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Applied Environmental Microbiology. 2012; 78(3): 744-51.
[20]	Sausset R, Petit MA, Gaboriau-Routhiau V, De Paepe M. New insights into intestinal phages. Mucosal Immunol. 2020 Mar; 13(2): 205-215.
[21]	Stanford K, McAllister TA, Niu YD, Stephens TP, Mazzocco A, Waddell TE, Johnson RP. Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in feedlot cattle. Journal of Food Protection. 2010; 73(7): 1304-12.
[22]	Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Journal of Pharmacy and Pharmacology. 2011; 63(10): 1253-64.
[23]	Rotman SG, Sumrall E, Ziadlou R, Grijpma DW, Richards RG, Eglin D, Moriarty TF. Local Bacteriophage Delivery for Treatment and Prevention of Bacterial Infections. Frontiers in Microbiology. 2020; 11: 538060.
[24]	Qadir MI. Review: phage therapy: a modern tool to control bacterial infections. Pakistan Journal of Pharmaceutical Science. 2015; 28(1): 265-70. PMID: 25553704.
[25]	McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrobial Agents and Chemotherapy. 2007; 51(6): 1934-8.
[26]	Uchiyama J, Maeda Y, Takemura I, Chess-Williams R, Wakiguchi H, Matsuzaki S. Blood kinetics of four intraperitoneally administered therapeutic candidate bacteriophages in healthy and neutropenic mice. Microbiology and Immunology. 2009; 53(5): 301-4.
[27]	Caldwell J. The importance of drug metabolism studies for efficient drug discovery and development. Drug Metabolism and Pharmacokinetics. 1996; 11: 119-126.
[28]	Merrill CR, Scholl D, Adhya S. Phage therapy. In: Calendar R, ed. The Bacteriophages. Second Edition. New York, NY: Oxford University Press. 2006; Pp. 725-741.
[29]	Kochetkova VA, Memento AS, Moskovtseva RL, Eastover EI, Trofimov EI, Popov MI, Kutateladze M, Adamia R. Bacteriophages potential as new therapeutics to replace or supplement antibiotics. Trends in Biotechnology. 2010; 28: 591-595.
[30]	Abed ST, Thomas-Abed C. Phage therapy pharmacology. Current Pharmaceutical Biotechnology. 2010; 11: 28-47.
[31]	Gorky A, Borysowski J, Miedzybrodzki R, Weber-Dabrowska B. Bacteriophages in medicine. In: McGrath S, van Sundered D, eds. Bacteriophage: Genetics and Microbiology. 2007; Pp.125-158.
[32]	Robert JH, Phil PD, Jansen VAA. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clinical Pharmacology and Therapeutics. 2000; 68: 225-230.
[33]	Summers WC. Felix Here’ll and the origins of molecular biology. Yale University Press, New Haven, Conn. 1999.
[34]	Wright A, Hawkins CH, Änggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: a preliminary report of efficacy. Journal of Clinical Otolaryngology. 2009; 34: 349-357.
[35]	Gonzalez-Menendez E, Fernandez L, Gutierrez D, Rodriguez A, Martinez B, Garcia P. Comparative analysis of different preservation techniques for the storage of Staphylococcus phages aimed for the industrial development of phage-based antimicrobial products. PLoS One. 2018; 13(10): e0205728.
[36]	Higgins JP, Higgins SE, Guenther K, Huff W, Donoghue AM. Use of specific bacteriophage treatment to reduce Salmonella in poultry products. Poultry Science. 2005; 84: 1141-1145.
[37]	Sillankorva S, Pleteneva E, Shaburova O, Santos S. Salmonella enteritidis bacteriophage candidates for phage therapy of poultry. Journal of Applied Microbiology. 2010; 108 (4): 1175-1186.
[38]	El-Shibiny A, Scott A, Times A, Matawan Y, Connerton P, Connerton I. Application of group II Campylobacter bacteriophages to reduce strains of Campylobacter jejuni and Campylobacter coli colonizing broiler chickens. Journal of Food Protection. 2009; 72: 733-740.
[39]	Bircher AJ, Lovell MA, Barrow PA. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella Typhimurium. Research in Microbiology. 1991; 142: 541-549.
[40]	Ngu NT, Phuong LNN, Anh LH, Loc HT, Tam NT, Huan PKN, Kamei K. The efficiency of bacteriophages against Salmonella Typhimurium infection in native Noi broilers. Brazilian Journal of Poultry Science. 2022; 24(3): eRBCA-2021.
[41]	Borie C, Albala P, Sanchez P, Sanchez M, Ramirez S. Bacteriophage treatment reduces Salmonella colonization of infected chickens. Avian Diseases. 2008; 52: 64-67.
[42]	Goodridge LD, Bashar B. Phage-based biocontrol strategies to reduce foodborne pathogens in foods. Bacteriophage. 2011; 1: 130-137.
[43]	Wall SK, Zhang J, Rostagno MH, Enbrel PD. Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Applied and Environmental Microbiology. 2010; 76:48-53.
[44]	Bach S, Johnson R, Stanford K, McAllister T. Bacteriophages reduce Escherichia coli O157:H7 levels in experimentally inoculated sheep. Foodborne Pathogens and Disease. 2009; 5: 183-191.
[45]	Chen SY, Wang JT, Chen TH, Lai MS, Chie WC, Chien KL, Hsueh PR, Wang JL, Chang SC. Impact of traditional hospital strain of methicillin-resistant Staphylococcus aureus (MRSA) and community strain of MRSA on mortality in patients with community-onset S. aureus bacteremia. Medicine (Baltimore). 2010; 89: 285-294.
[46]	Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proceedings of the National Academy of Sciences. 2009; 106: 4629-4634.
[47]	Sulakvelidze A. Safety by nature: potential bacteriophage applications. Microbe. 2011; 6(3): 122-126.
[48]	Lantos E, Bamford JK, Leaks J, Sandburg LR. Phage-driven loss of virulence in a fish pathogenic bacterium. PLoS One. 2012; 7 (12): e53157.
[49]	Chan B, Abedon S. Phage therapy pharmacology phage cocktails. Advances in Applied Microbiology. 2012; 78: 1-23.
[50]	Merrill CR, Scholl D, Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nature Reviews Drug Discovery. 2003; 2(6): 489-497.
[51]	Summers WC. Bacteriophage therapy. Annual Review of Microbiology. 2011; 55: 437-451.
[52]	Lock-Carrillo C, Abed ST. Pros and cons of phage therapy. Bacteriophage. 2011; 1:111-114.
[53]	Matsuzaki S, Rashes M, Uchiyama J, Sakurai S. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. Journal of Infection and Chemotherapy. 2005; 11: 211-219.
[54]	Friman VP, Histone T, Jalasvuori M, Lindstedt C. High temperature and bacteriophages can indirectly select for bacterial pathogenicity in environmental reservoirs. PLoS One. 2011; 6(3): e17651.
[55]	Story L, Weber-Dabrowska B, Parka K, Mulczyk M, Wojcik M. Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn. Neurologia i Neurochirurgia Polska. 2000; 3: 693-698.
[56]	Fajardo-Lubian A, Venturini C. Use of bacteriophages to target intracellular pathogens. Clinical Infectious Diseases. 2023; 77: S423-S432.
[57]	Merrill CR, Bias B, Carlton R, Jensen NC, Creed GJ, Zulus S, Adhya S. Long-circulating bacteriophage as antibacterial agents. Proceedings of the National Academy of Sciences USA. 1996; 8: 3188-3192.